Fractyl Health Q1 2026 EPS Beat, Shares Surge 23%

Fractyl Health Q1 2026 EPS beat expectations by 76%, shares surged 23% after hours. Revita program data expected in Q4 2026.

ByAria Wright- Senior Editor

Today / 13:10|Last updated: Today / 13:12

Fractyl Health Q1 2026 EPS Beat, Shares Surge 23% — Photo: Prepared by Bond.az

Fractyl Health (NASDAQ:GUTS) reported Q1 2026 earnings with an EPS of -$0.06, beating the forecast of -$0.25 by 76%.

Despite zero revenue, the stock surged 23.32% in after-hours trading to $0.9483, reflecting investor optimism.

The company improved net loss from $23.7 million in Q1 2025 to net income of $9.2 million, driven by non-cash warrant liability adjustments.

Fractyl Health is focused on its Revita program, with pivotal trial data expected in early Q4 2026.

More News

Driven Brands Q4 2025 Revenue Growth Reported

Today / 13:43

246

Driven Brands Q4 2025 Revenue Growth Reported

Driven Brands Q4 2025 revenue grows 7.7% to $460.1M, EPS $0.34. Stock up 1.12%.

TRANSCRIPTS →

Today / 13:41

777

Ceragon Q1 2026 Revenue Beats Estimates

Ceragon Networks Q1 2026 revenue beat estimates at $85M. EPS $0.01. Stock rose 6.77% premarket. Full-year guidance reiterated.

TRANSCRIPTS →

Antalpha Q1 2026: EPS Misses Forecast, Stock Rises

Today / 13:01

272

Antalpha Q1 2026: EPS Misses Forecast, Stock Rises

Antalpha Q1 2026: EPS misses forecast at $0.07, stock rises 2.42%. Revenue up 52% to $20.7M. Web3 AI agent Nina launched. Q2 guidance $11M-$13M.

TRANSCRIPTS →

GNFC Q4 profit surges, stock climbs 5.17%

Today / 12:44

314

GNFC Q4 profit surges, stock climbs 5.17%

GNFC Q4 FY2026 strong results: revenue up 11%, PAT up 35%, stock rises 5.17%. Chemical segment drives growth.

TRANSCRIPTS →

Today / 12:42

677

Relmada TX Q1 2026: Loss and stock dip

Relmada Therapeutics Q1 2026 results: stock declines, strong cash position and NDV-01 program in focus.

TRANSCRIPTS →

Inovio Beats Q1 2026 EPS Forecast, Stock Slips

Today / 12:00

958

Inovio Beats Q1 2026 EPS Forecast, Stock Slips

Inovio Q1 2026 EPS beats forecasts, but stock falls. Detailed financial analysis and outlook on Bond.az.

TRANSCRIPTS →

CytoSorbents Q1 2026 Misses Forecasts, Stock Falls

Today / 11:50

449

CytoSorbents Q1 2026 Misses Forecasts, Stock Falls

CytoSorbents Q1 2026 results: EPS of -$0.05 misses estimate, revenue of $8.9M falls short, stock drops 7.53%. Company cuts costs and targets breakeven in H2 2026.

TRANSCRIPTS →

Today / 10:53

859

IOC Q4 2026 earnings beat expectations

IOC Q4 2026 earnings beat expectations with EPS of 6.15, a 20.59% surprise. Stock rose 2.42%. Record refining throughput and 184% profit growth reported.

TRANSCRIPTS →

Dr. Martens Q2 2026: revenue dip, stock surges

Today / 09:55

635

Dr. Martens Q2 2026: revenue dip, stock surges

Dr. Martens Q2 2026 earnings: stock surges 8.41% despite revenue dip. Consumer-first strategy drives profit growth. Undervalued according to Bond.az analysis.

TRANSCRIPTS →

Today / 09:54

646

SSP Group H1 2026 shows strong growth

SSP Group H1 2026 revenue up 6%, EPS turns positive. Shares rise 2.92% on strong results.

TRANSCRIPTS →

Today / 09:32

982

Pfisterer Holding SE strong Q1 results

Pfisterer Holding SE reports 26.7% revenue growth and 57.7% EPS surge in Q1 2026. Order book up 17.7% to EUR 188 million.

TRANSCRIPTS →

Today / 08:10

843

ICMB Q1 2026 Earnings Miss Expectations

Investcorp Credit Management BDC (ICMB) reported disappointing Q1 2026 results, missing EPS and revenue estimates. Stock drops 4.95%.

TRANSCRIPTS →

...